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Background: The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT)
in prostate cancer (PCa) has not been well defined yet. Because high-grade PCa tends to exhibit increased glycolytic
rate, FDG-PET/CT could be useful in this setting. The aim of this study was to assess the value of FDG-PET/CT
for pre-operative staging and prognostic stratification of patients with high-grade PCa at biopsy.
Methods: Fifty-four patients with a Gleason sum ≥8 PCa at biopsy underwent FDG-PET/CT as part of the staging
workup. Thirty-nine patients underwent radical prostatectomy (RP) and pelvic lymph node (LN) dissection, 2 underwent
LN dissection only, and 13 underwent non-surgical treatments. FDG-PET/CT findings from clinical reports, blinded
reading and quantitative analysis were correlated with clinico-pathological characteristics at RP.
Results: Suspicious foci of increased FDG uptake were found in the prostate, LNs and bones in 44, 13 and 6% of
patients, respectively. Higher clinical stage, post-RP Gleason sum and pattern, and percentage of cancer involvement
within the prostate were significantly associated with the presence of intraprostatic FDG uptake (IPFU) (P < 0.05 in all
cases). Patients without IPFU who underwent RP were downgraded to Gleason ≤7 in 84.6% of cases, as compared to
30.8% when IPFU was reported (P = 0.003). Qualitative and quantitative IPFU were significantly positively correlated with
post-RP Gleason pattern and sum, and pathological T stage. Absence and presence of IPFU were associated with a
median 5-year cancer-free survival probability of 70.2 and 26.9% (P = 0.0097), respectively, using the CAPRA-S prognostic
tool.
Conclusion: These results suggest that, among patients with a high-grade PCa at biopsy, FDG-PET/CT could
improve pre-treatment prognostic stratification by predicting primary PCa pathological grade and survival
probability following RP.
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Staging and prognostication of primary prostate cancer
(PCa) is of prime importance, especially for aggressive
PCa, for which failure rate to local therapy is high [1].
Over the last decades, a number of clinical tools such as* Correspondence: frederic.pouliot@crchuq.ulaval.ca
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unless otherwise stated.nomograms and imaging technologies have gained wide
acceptance, but their accuracy for pre-treatment staging
and prognostication is limited.
Molecular imaging with positron emission tomog-
raphy/computed tomography (PET/CT) can detect mo-
lecular changes within cancer cells before morphological
changes become apparent on conventional anatomical
imaging such as standalone CT or magnetic resonance
imaging [2]. The most widely used PET/CT application
is the assessment of glucose metabolism using the glu-
cose analogue 18F-fluorodeoxyglucose (FDG) [3]. FDGtral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and aggressiveness for many cancers, including metastatic
PCa [4,5]. Nevertheless, FDG-PET/CT is not routinely
performed in PCa patients, as low FDG accumulation in
the majority of PCa tumours, which tend to be indolent,
has been perceived as a major limitation. Also, early stud-
ies often included small and/or heterogeneous cohorts of
patients with respect to clinical stage and grade of the dis-
ease, and many results were obtained using standalone
PET rather than PET/CT [3,6,7]. More recent clinical data
have shown that FDG uptake tends to increase in more
aggressive PCa, either recurrent or metastatic [4,5,8,9].
For instance, Beauregard et al. found a detection rate of
69% for FDG-PET/CT, compared to 13% for conventional
imaging (CT and bone scan) in 16 patients evaluated for
staging or restaging of non-low-risk PCa [9]. Furthermore,
overexpression of glucose transporters has been evidenced
in high-Gleason score PCa [10,11]. We therefore hypothe-
sized that FDG-PET/CT might be useful in the initial sta-
ging and prognostication of high-grade PCa (Gleason ≥8)
at biopsy.Methods
Patients
Fifty-four patients newly diagnosed with a Gleason sum
≥8 adenocarcinoma of the prostate at 12-core transrectal
ultrasound-guided prostate biopsy were referred for a
staging FDG-PET/CT at CHU de Québec, in addition to
whole-body bone scan. Patients with a prior history of
malignancy within 5 years were excluded. Baseline
patient characteristics are summarized in Table 1. TheTable 1 Patient baseline characteristics
Surgical patients (n = 41) No
No. (%) Median (range) No
Age, years 67.5 (48.7-75.5)
Biopsy Gleason score* 8 32 (78.0) 4 (
9 9 (22.0) 9 (
Pretreatment PSA (ng/ml) 7.0 (1.7-57.0)
<10.0 31 (75.6) 5 (
10.0-19.9 9 (22.0) 3 (
≥20.0 1 (2.4) 5 (
Clinical T stage† cT1 15 (36.6) 3 (
cT2 14 (34.1) 2 (
cT3 6 (14.6) 5 (
cT4 0 (0.0) 3 (
n/a 6 (14.6) 0 (
PSA = prostate-specific antigen; n/a = not available.
*Based on 2005 International Society of Urological Pathology Modified Gleason Sys
†Based on American Joint Committee on Cancer, 7th ed.institutional Ethics committee approved this retrospect-
ive study.FDG-PET/CT
Patients were asked to fast for 6 hours and their glycaemia
was checked. FDG-PET/CT was performed approximately
75 minutes after the administration of 300–500 MBq
FDG, with oral contrast, from base of skull to upper
thighs, on a Biograph 6 PET/CT system (Siemens Health-
care, Erlangen, Germany).
Clinical reporting of FDG-PET/CT was performed by
one of three attending nuclear medicine physicians,
using a Syngo MI workstation (Siemens Healthcare).
The presence or absence of suspicious FDG uptake in the
prostate (intraprostatic FDG uptake or IPFU), regional
lymph nodes (LNs) and distant sites was extracted from
the clinical reports. More than 8 months after the last
patient accrual, one nuclear medicine physician (J.M.B.)
reviewed the FDG-PET/CT images blinded to the clinical
PET/CT report and any clinical data other than the impli-
cit knowledge that all patients had a biopsy-proven high-
grade PCa, and scored the IPFU as follows: 0) no focal
uptake above background; focal uptake of 1) mild – less
than liver, 2) moderate – similar to liver, 3) intense – more
than liver, or 4) very intense level – much more than liver.
Scores 0 and 1 were considered negative, while scores 2 to
4 were considered positive for significant IPFU. The pros-
tatic maximum standardized uptake value for body weight
(SUVmax) was measured independently, with caution to
exclude any urinary activity. SUVmax <4.0 was considered
negative for IPFU and ≥ 4.0, positive. In one patient, then-surgical patients (n = 13) All patients (n = 54) P-value
. (%) Median (range) No. (%) Median (range)
65.8 (50.0-82.6) 66.3 (48.6-82.6) 0.77
30.8) 36 (66.7) 0.005
69.2) 18 (33.3)










Figure 1 Study scheme (TRUS = transrectal ultrasound; RP =
radical prostatectomy; ePLND= extended pelvic lymph node
dissection; ADT = androgen deprivation therapy; XRT = radiation
therapy).
Beauregard et al. Cancer Imaging  (2015) 15:2 Page 3 of 10SUVmax was invalid due to an error in uptake time data
entry and this patient was excluded from the quantitative
analysis.
Primary treatment
Patients were offered the best of care treatment depend-
ing on their co-morbidities, metastatic status and/or
preference. When radical prostatectomy (RP) was se-
lected, an extended bilateral pelvic LN dissection (PLND)
was performed first. The PLND consisted in the removal
of common iliac, internal iliac, external iliac and obtur-
ator LNs. Non-surgical patients were treated with andro-
gen deprivation therapy (ADT) alone or in combination
with radiation therapy (RT). Patients managed non-
operatively and with metastasis on staging FDG-PET/CT
were re-imaged after at least 3 months of ADT to evalu-
ate therapeutic response. Lesions with a radiological
response/progression consistent with the biochemical
evolution were considered true positive.
Pathological assessment
The following results were extracted from the clinical
pathology reports: PCa involvement by sextant, percent-
age of prostatic tissue involved, pathological stage,
pathological Gleason pattern and sum, LNs status and
location.
Statistical analyses
Two validated post-operative prognostic tools that use
clinico-pathological data to predict progression-free sur-
vival at 5 years were used: the CAPRA-S scores from
University of California, San Francisco (UCSF) and the
MSKCC nomogram from Memorial Sloan-Kettering
Cancer Center [12-15]. Statistical tests were done using
SAS v.9.3 software. Univariate analysis was performed
using Pearson’s chi-squared and Fisher’s exact tests.
Mann–Whitney U test was used for two-group compari-
sons. Spearman correlations were performed for ordinal




Forty-one patients underwent surgery (Figure 1). Of
these, 39 had RP and PLND, while 2 had PLND only
due to metastatic LN disease found at the time of sur-
gery. Of the 41 operated patients, 11 (26.8%) were found
to harbour LN metastasis at pathology. The remaining
13 patients were treated with ADT, with or without RT.
Baseline characteristics of the surgical and the non-
surgical groups are compared in Table 1. Pathological
data for surgical patients are summarized in Table 2.
Among the 39 patients who underwent RP, the Gleason
sum was downgraded from ≥8 at biopsy to ≤7 followingRP in 26 patients (66.7%). All patients were followed-up
for a median of 20 months (range: 15 to 24 months).
FDG-PET/CT
FDG-PET/CT results from clinical reports, blinded quali-
tative reading and quantitative analysis are presented on a
per-patient basis in Table 3 and examples are depicted in
Figure 2. The three patients with bone disease had their
bone metastases detected by both FDG-PET/CT and bone
scan (Figure 3). Of 7 patients with suspected LN metasta-
sis on FDG-PET/CT, 3 had pathological confirmation at
surgery and 4 had metabolic response after 3 months of
ADT, consistent with a specificity of 100%. FDG-PET/CT
detected LN metastases in 3/11 (27%) patients with
pathology-proven LN disease at surgery.
IPFU vs. clinico-pathological characteristics
The associations between 10 clinico-pathological fea-
tures and IPFU status are presented in Table 4. IPFU as
described in clinical reports was statistically significantly
associated with clinical stage, pathological Gleason sum,
pathological Gleason pattern and the percentage of pros-
tatic tissue involved by PCa (Table 4). Based on clinical
reporting, negative IPFU conferred patients a 84.6%
probability of being downgraded to Gleason sum ≤7 at
RP, which contrasts with a downgrading probability of
30.8% when IPFU was reported (Table 5). Moreover, all
cases of Gleason sum 9 PCa post-RP did have IPFU,
while none of the primary Gleason score 3 did.
Table 2 Pathological characteristics of surgical patients
(n = 41)*
No. (%)




Gleason pattern† 3 + 3 2 (5.1)
3 + 4 8 (20.5)
3 + 5 1 (2.6)
4 + 3 16 (41.0)
4 + 4 8 (20.5)
4 + 5 3 (7.7)
5 + 4 1 (2.6)








Margins Negative 23 (59.0)
Positive 16 (41.0)
Extracapsular extension No 21 (53.8)
Yes 18 (46.2)
SV invasion No 28 (71.8)
Yes 11 (28.2)
Perineural invasion No 5 (12.8)
Yes 19 (48.7)
n/a 15 (38.5)
Intraprostatic cancer extent (Mean % (SD)) - 27.3 (22.9)
Pathological N stage‡ pN0 30 (73.2)
pN1 11 (26.8)
Number of LN (Mean (SD)) - 17.6 (7.3)
LN density (Mean (SD)) - 3.6 (8.3)
LN = lymph nodes; SD = standard deviation; SV = seminal vesicles;
n/a = not available.
*39 patients underwent radical prostatectomy with extended pelvic lymph
node dissection and 2 patients underwent extended pelvic lymph node
dissection only.
†Based on 2005 International Society of Urological Pathology Modified
Gleason System.
‡Based on American Joint Committee on Cancer, 7th ed.






patients (n = 13)
No. (%) No. (%) No. (%)
Clinical report
IPFU+ 24 (44.4) 15 (36.6) 9 (69.2)
Lymph node
metastasis
7 (13.0) 3 (7.3) 4 (30.8)
Bone metastasis 3 (6.0) 0 (0.0) 3 (23.1)
Blinded reading*
IPFU score 0 6 (11.1) 6 (14.6) 0 (0.0)
IPFU score 1 18 (33.3) 15 (36.6) 3 (23.1)
IPFU score 2 14 (25.9) 12 (29.3) 2 (15.3)
IPFU score 3 10 (18.5) 6 (14.6) 4 (30.8)
IPFU score 4 6 (11.1) 2 (4.9) 4 (30.8)
IPFU+ (score 2
to 4)




24 (44.4) 15 (36.6) 9 (69.2)
Median (range) Median (range) Median (range)
Prostatic SUVmax 3.7 (1.8 – 34.7) 3.5 (1.8 – 24.9) 5.9 (2.5 – 34.7)
FDG = 18F-fluorodeoxyglucose; IPFU = intraprostatic FDG uptake; IPFU + =
IPFU-positive; SUVmax = maximum standardized uptake value.
*Blinded FDG-PET/CT reading resulted in exactly the same detection rates of
lymph node and bone metastasis as the clinical reading.
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tistically significantly associated with pathological Gleason
sum and percentage of intraprostatic cancer (Table 4).
SUVmax was significantly higher in patients with Gleason
sum ≥8 than those with Gleason sum ≤7 at final pathology(6.62 ± 6.25 vs. 3.53 ± 1.32, respectively; P = 0.020), and
SUVmax ≥4 was significantly associated with pathological
Gleason sum ≥8 (Table 5). Conversely, in 39 patients who
underwent RP, low IPFU (SUVmax <4.0) conferred patients
an 83.3% probability of the Gleason sum being down-
graded from ≥8 at biopsy to ≤7 at pathology. This prob-
ability was 85.0% when using qualitative IPFU assessment
from the blinded reading (Table 5).
Statistically significant positive correlations were found
between SUVmax and visual uptake score on one hand,
and post-RP Gleason pattern, Gleason sum and patho-
logical T stage on the other hand (Table 5 and Figure 4).
IPFU vs. post-radical prostatectomy prognosis
IPFU was compared with the predicted 5-year progres-
sion-free survival, as determined by the CAPRA-S and
MSKCC nomograms (Table 6) [12-15]. There was a
statistically significant difference in predicted 5-year
progression-free survival between patients with or with-
out significant IPFU.
Discussion
Treatment decision after PCa diagnosis is complicated
by the variability of disease progression and the diversity
of treatments available. To predict PCa behaviour, a
number of clinical tools have been developed. One of
Figure 2 Examples of corresponding transaxial PET (A, D), fused PET/CT (B, E) and CT (C, F) slices. A patient (A-C) had a Gleason sum 8 (4 + 4)
PCa at biopsy and the most prominent focus of prostatic FDG uptake was only faintly noticeable (negative clinical report; Score = 1; SUVmax = 2.7).
His PCa was downgraded to Gleason sum 6 (3 + 3) after RP. Conversely, another patient (D-F) also had a Gleason sum 8 (4 + 4) PCa at biopsy, but
FDG-PET/CT showed a highly hypermetabolic prostatic focus (positive clinical report; Score = 3; SUVmax = 8.2). His PCa was upgraded to Gleason sum 9
(5 + 4) following RP.
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guidelines are based on this classification for treatment
recommendations [16,17]. However, the high-risk category
includes a wide range of tumour volumes and PSA levels,
and also biologically heterogeneous tumours, some being
high-grade, highly aggressive tumours (Gleason 9–10),
while other being downgraded to Gleason ≤7 at post-RP
pathology. Indeed, for high-risk PCa, there is a need for
better pre-treatment disease characterization to optimize
treatment strategy. Staging is of prime importance in this
setting because loco-regional treatment with RP and/or
RT is rarely curative when there is LN metastasis. But
radiological size-based LN metastasis detection has a poor
accuracy [18].
In the last two decades, a number of PET radiophar-
maceuticals have been developed for PCa. Of these, 11C-
choline and 18F-fluorocholine (FCH) have been the most
studied clinically [19]. Choline radiopharmaceuticals are
reputed having a higher uptake in PCa cells than FDG
[19], although this is not well established specifically for
high-grade PCa. Recent studies in large cohorts have
shown promising results for FCH-PET/CT as a staging
tool. For example, Beheshti et al. have shown that FCH-
PET sensitivity and specificity for PCa LN metastasis de-
tection were 66% and 96%, respectively [20]. Therefore,
by comparing these results to ours (27% LN detection
sensitivity in surgical patients, 47% overall), it seems that
FCH may be superior to FDG for PCa LN staging. More
recently, Haseebuddin et al. studied the role of 11C-acet-
ate-PET/CT in the primary staging of intermediate and
high-risk PCa with negative conventional imaging [21].They reported a significant difference in 3-year treat-
ment failure probability of 82 and 51%, respectively,
when metastasis was found or not, respectively, on pre-
operative 11C-acetate imaging. One could suggest that
LN positivity on FCH- or 11C-acetate-PET would carry a
greater prognostic value than IPFU, but this is question-
able. In fact, reported recurrence-free status at 5 years in
patients harbouring pN1 disease (without adjuvant ADT)
is approximately 20 to 26% [22,23]. This is similar to the
percentage of patients predicted to be disease-free at
5 years by CAPRA-S nomogram when IPFU is present,
which was 26.9% in our series. Moreover, 27% (3/11) of
pathologically-proven LN metastasis were identified by
FDG-PET/CT and the two patients for whom CAPRA-S
calculation was possible (one did not undergo RP) had a
predicted 5-year recurrence-free survival of 0%. This
shows the potentially enhanced discriminative prognostic
capability of the widely available FDG radiopharmaceutical
compared with choline or acetate tracers.
Moreover, in our series, FCH-PET would theoretically
have identified only 7 patients with LN metastasis (66%
of 11 pN1) while FDG-PET identified 15 patients with a
high local treatment failure probability based on IPFU.
Indeed, the tumour biology (or intrinsic aggressiveness)
might be as important to consider pre-operatively as LN
staging, since some aggressive cancers will metastasize
systemically, skipping LN transition. This is consistent
with the observation that 2 out of our 3 patients with
bone metastasis had IPFU and FDG-positive bone me-
tastasis without any evidence of LN metastasis. In their
series of metastatic castration-resistant PCa (CRPC)
Figure 3 Fused FDG-PET/CT transaxial slices in a patient with a Gleason sum 9 (4 + 5) PCa at biopsy showing (A) a highly hypermetabolic
prostatic focus (positive clinical report; score = 3; SUVmax = 7.1) and (C) one of two bone metastases, which were intensely hypermetabolic
and lytic on CT (E). Three months after ADT initiation, there was a complete metabolic response of the primary PCa lesion (B). The bone lesions
underwent at least a partial metabolic response (D) and became sclerotic on CT (F). Possibly, the osteoblasts repair activity contributed to the residual
FDG uptake. The metabolic response was consistent with the biochemical response, with the PSA decreasing from 125 to 1.5 ng/L.
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their patients had bone-only metastases while 5.7% had
both bone and soft tissue metastases [5]. This suggests
that radiological and/or surgical LN staging is insuffi-
cient for prognostic stratification of high-grade PCa
patients. Taken together, these results suggest that FDG-
PET/CT, as a single imaging modality, can identify many
patients at high risk of local treatment failure, possibly
with better discriminative prognostic capability than
choline- or acetate-PET. Prospective trials directly com-
paring FDG with these tracers in patients with high-
grade PCa at biopsy are warranted to ascertain this
hypothesis.
The prognostic capability of FDG-PET/CT in high-
grade PCa is not counterintuitive. The prognostic value
of FDG-PET/CT was shown in patients with metastatic
PCa by Meirelles et al., who reported that FDG uptakein metastatic lesions of 51 patients (39 CRPC and 12
castration-sensitive) was correlated to prognosis [4].
Jadvar et al. reported that the summed FDG uptake
(SUVmax) of metastatic lesions could predict overall
survival in a large cohort of 87 CRPC patients [5]. In
our series, higher metabolic activity of the primary
PCa correlated strongly with higher pathological Gleason
sum and predicted nomogram-derived prognosis. To-
gether, these results suggest that PCa with higher glu-
cose metabolism is associated with a poorer prognosis,
both at early and late stages of the disease evolution.
Whether increased FDG uptake is maintained through-
out the course of the disease or acquired after clonal
selection under ADT remains to be elucidated, but
early identification of IPFU might prompt a more
aggressive systemic management, even in apparently
localized PCa.
Table 4 Clinico-pathological features associated with intraprostatic FDG uptake
Clinical reporting Quantitative analysis
IPFU- IPFU+ P-value SUVmax <4.0 SUVmax ≥4.0 P-value
No. (%) No. (%) No. (%) No. (%)
Clinical T stage* cT1 12 (48.0) 6 (26.1) 0.042 12 (50.0) 6 (27.3) 0.13
cT2 10 (40.0) 6 (26.1) 9 (37.5) 7 (31.8)
cT3 3 (12.0) 8 (34.8) 3 (12.5) 7 (31.8)
cT4 0 (0.0) 3 (13.0) 0 (0.0) 2 (9.1)
Pretreatment PSA (ng/ml) <10.0 23 (76.7) 13 (54.2) 0.21 23 (79.3) 12 (52.2) 0.12
10.0-19.9 5 (16.7) 7 (29.2) 4 (13.8) 7 (30.4)
≥20.0 2 (6.7) 4 (16.7) 2 (6.9) 4 (17.4)
Pathological T stage* pT2 14 (53.8) 5 (38.5) 0.28 14 (58.3) 5 (35.7) 0.17
pT3 12 (46.2) 7 (53.8) 10 (41.7) 8 (57.1)
pT4 0 (0.0) 1 (7.7) 0 (0.0) 1 (7.1)
Pathological N stage* pN0 21 (80.8) 9 (60.0) 0.15 21 (84.0) 9 (60.0) 0.090
pN1 5 (19.2) 6 (40.0) 4 (16.0) 6 (40.0)
Gleason score† 6 3 (11.5) 0 (0.0) 0.002 3 (12.5) 0 (0.0) 0.029
7 19 (73.1) 4 (30.8) 17 (70.8) 6 (42.9)
8 4 (15.4) 5 (38.5) 4 (16.7) 5 (35.7)
9 0 (0.0) 4 (30.8) 0 (0.0) 3 (21.4)
Gleason pattern† 3 + 3 2 (7.7) 0 (0.0) 0.009 2 (8.3) 0 (0.0) 0.062
3 + 4 8 (30.8) 0 (0.0) 7 (29.2) 1 (7.1)
3 + 5 1 (3.8) 0 (0.0) 1 (4.2) 0 (0.0)
4 + 3 12 (46.2) 4 (30.8) 11 (45.8) 5 (35.7)
4 + 4 3 (11.5) 5 (38.5) 3 (12.5) 5 (35.7)
4 + 5 0 (0.0) 3 (23.1) 0 (0.0) 2 (14.3)
5 + 4 0 (0.0) 1 (7.7) 0 (0.0) 1 (7.1)
Intraprostatic cancer extent 0-9% 8 (30.8) 0 (0.0) 0.027 8 (33.3) 0 (0.0) 0.046
10-49% 15 (57.7) 7 (58.3) 13 (54.2) 9 (69.2)
≥50% 3 (11.5) 5 (41.7) 3 (12.5) 4 (30.8)
Margins Negative 15 (57.7) 8 (61.5) 0.82 15 (62.5) 8 (57.1) 0.74
Positive 11 (42.3) 5 (38.5) 9 (37.5) 6 (42.9)
Extracapsular extension No 15 (57.7) 6 (46.2) 0.50 15 (62.5) 6 (42.9) 0.24
Yes 11 (42.3) 7 (53.8) 9 (37.5) 8 (57.1)
SV invasion No 20 (76.9) 8 (61.5) 0.31 19 (79.2) 8 (57.1) 0.15
Yes 6 (23.1) 5 (38.5) 5 (20.8) 6 (42.9)
FDG = 18F-fluorodeoxyglucose; IPFU = intraprostatic FDG uptake; IPFU- = IPFU-negative; IPFU+ = IPFU-positive; PSA = prostate-specific antigen; SV = seminal vesicles.
*Based on American Joint Committee on Cancer, 7th ed.
†Based on 2005 International Society of Urological Pathology Modified Gleason System.
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choline-PET is its ability to predict post-RP Gleason
sum and pattern. Most choline-PET studies did not
find any correlation between intraprostatic choline up-
take and Gleason sum [24-26]. In our study, negative
IPFU indicated an 84.6% probability that a patient
would be downgraded to Gleason ≤7 at RP. Moreover,
there was a significant correlation between IPFU
(SUVmax and score) and post-RP Gleason pattern andsum. A potential role for FDG-PET/CT could be the
assessment of IPFU to guide adjuvant ADT duration
decisions when RT is the primary treatment. The opti-
mal length of ADT in D’Amico’s high-risk patients is
still debated, and it may be that IPFU-negative patients
could be suitable for shorter ADT duration. FDG-
PET/CT could also prospectively identify patients for
whom peri-operative chemotherapy or new ADT drugs
could be beneficial.
Table 5 Intraprostatic FDG uptake as a predictor of pathological Gleason sum
Pathological Gleason sum Spearman r P-value
≤7 ≥8
No. (%) No. (%)
Clinical reporting
IPFU- 22 (84.6) 4 (15.4) 0.003
IPFU+ 4 (30.8) 9 (69.2)
Blinded reading
IPFU- (Score 0 or 1) 17 (85.0) 3 (15.0) 0.013
IPFU+ (Score 2 to 4) 9 (47.4) 10 (52.6)
Score vs. post-RP Gleason pattern 0.58 0.0001
Score vs. post-RP Gleason sum 0.50 0.001
Score vs. pathological T stage 0.32 0.040
Quantitative analysis
IPFU- (SUVmax < 4.0) 20 (83.3) 4 (16.7) 0.010
IPFU+ (SUVmax ≥ 4.0) 6 (42.9) 8 (57.1)
SUVmax vs. post-RP Gleason pattern 0.46 0.004
SUVmax vs. post-RP Gleason sum 0.44 0.006
SUVmax vs. pathological T stage 0.35 0.030
FDG = 18F-fluorodeoxyglucose; IPFU = intraprostatic FDG uptake; IPFU- = IPFU-negative; IPFU + = IPFU-positive; RP = radical prostatectomy; SUVmax = maximum
standardized uptake value.
Table 6 Intraprostatic FDG uptake as a predictor of the











IPFU- 70.2 (26.7 – 85.2) 0.008 91.5 (77.0 – 97.0) 0.004
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reporting of FDG-PET/CT may have been biased by the
variability among attending nuclear medicine physicians
in their interpretation of what constitutes significant or
suspicious IPFU. However, the systematic blinded read-
ing with qualitative IPFU assessment and the quantita-
tive analysis both corroborate the results derived from
clinical reporting. Secondly, most conclusions are based
on the surgical subgroup. Because treatment decision
was left to the surgeon and the patient (standard of
care), many cases of FDG-positive LN or bone metasta-
sis and/or unresectable disease could not be verified
pathologically. Since all of them had a metabolicFigure 4 Prostatic FDG uptake vs. post-RP Gleason sum.
IPFU+ 25.9 (0.0 – 42.5) 59.0 (42.0 – 88.0)
Blinded reading
IPFU-
(Score 0 or 1)
70.2 (34.2 – 91.0) 0.017 93.0 (81.0 – 97.5) 0.010
IPFU+
(Score 2 to 4)




70.2 (26.7 – 85.2) 0.030 91.5 (72.8 – 97.0) 0.020
IPFU+
(SUVmax ≥ 4.0)
25.9 (0.0 – 42.5) 72.0 (45.0 – 89.0)
FDG = 18F-fluorodeoxyglucose; IPFU = intraprostatic FDG uptake; IPFU- = IPFU-
negative; IPFU + = IPFU-positive; SUVmax = maximum standardized uptake
value.
*University of California, San Franciso Cancer of the Prostate Risk Assessment
score: Post-Radical Prostatectomy nomogram.
†Memorial Sloan-Kettering Cancer Center post-radical prostatectomy
nomogram.
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metastatic status was probably true positive. Likely, the
LN sensitivity of 27% in our surgical group is an under-
estimation of the overall sensitivity of FDG for detection
of LN metastasis, which may be closer to 47% (7/15,
when including the 4 non-surgical patients with FDG-
positive LN). Finally, IPFU’s prognostic ability was shown
indirectly using two prognostic nomograms, the CAPRA-S
and the MSKCC. Certainly, the gold standard to demon-
strate the prognostic value of FDG-PET/CT will be our
cohort’s actual progression-free survival, which will be
assessed in the upcoming years. However, we are confident
that the estimated prognostic ability of FDG-PET/CT is real
since it is based on two of the most validated prognostic
tools [12-15]. Moreover, we have shown that IPFU was
associated with higher pathological Gleason sum and pat-
tern, and percentage of intraprostatic cancer, all of which
have been described as being of prognostic value [15,27,28].
Hence, it is highly expected that actual progression-free
survival will be different between low/negative and high/
positive IPFU, as the latter might represent the integration
of these poor-prognosis pathological features that are only
known after surgery.
Conclusions
Our results suggest that molecular imaging of patients
with high-grade PCa at biopsy using FDG-PET/CT could
be useful for both staging and prognostic stratification.
Intraprostatic FDG uptake assessment with PET/CT
may represent the integration of a number of important
pathological features, making this crucial prognostic
information available before primary therapy. Hence,
FDG-PET/CT has the potential to enable improved and
personalized care management in this selected PCa
patient population, which is most at risk of therapy fail-
ure and shortened survival.
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